Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs VICI Properties Inc (VICI) Price & Performance

Inovio Pharmaceuticals IncTrade
VICI Properties IncTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs VICI Properties Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.75 (market cap $78.55M), while VICI Properties Inc trades at $25.98 (market cap $28.61B). The key difference: VICI Properties Inc is far larger — about 364.2× Inovio Pharmaceuticals Inc's market cap, and VICI Properties Inc pays a 6.93% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

INOVICI
Market Cap
$78.55M$28.61B
Sector
HealthReal Estate
52-Week High
$2.87$33.78
52-Week Low
$0.66$25.94
Enterprise Value
$49.56M$46.16B
Dividend Yield
6.93%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.

Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.

VICI Properties Inc

VICI Properties trades at $25.99, down 0.33% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed Q2 2026 earnings with an EPS miss but revenue beat, while maintaining strong profitability margins near 67%. Recent news highlights a $1.75 billion notes offering and positive dividend coverage, with analysts largely bullish.

Outlook remains positive given a 6.6% dividend yield, low P/E of 10.07, and consensus price target of $29.83 implying 15% upside. Risks include earnings volatility, high leverage with $843.61M interest expense, and macroeconomic sensitivity affecting real estate valuations.

Returns comparison

Trailing returns across standard periods

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About VICI Properties Inc

VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.

Read more on VICI